Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIVIS
- Development stage
- Phase 2
- Lead developer
- Swedish Institute for Infectious Disease Control
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
HIVIS (HIV Vaccine Immunogenicity Study) refers to a prime-boost HIV-1 vaccine regimen developed through a collaboration between the Karolinska Institutet, the Swedish Institute for Infectious Disease Control (SMI), and the Muhimbili University of Health and Allied Sciences (MUHAS). The regimen typically consists of a multi-plasmid DNA vaccine (HIV-DNA) as a primer, followed by a recombinant Modified Vaccinia Ankara (MVA) virus vaccine (HIV-MVA) as a boost. The DNA component contains a mixture of plasmids encoding HIV-1 subtypes A, B, and C antigens, including Gag, Pol, Env, and Rev. The MVA boost expresses similar antigens to broaden and strengthen the cellular and humoral immune responses. The regimen has been evaluated in several Phase I and II clinical trials in East Africa, exploring various delivery methods such as intradermal injection with electroporation to enhance immunogenicity.
- Other names
- HIVIS vaccine regimenHIVIS DNA vaccineHIVIS MVA vaccineHIV Vaccine Immunogenicity Study
02
Targets
Gag (HIV-1 Gag polyprotein)Human immunodeficiency virus type 1 reverse transcriptaseRev (HIV-1 Rev)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on HIVIS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIVIS.